Paclitaxel-Cisplatin combination chemotherapy as first-line treatment of epithelial ovarian cancer (EOC) is known to cause myelosuppression that leads to decrease hemoglobin, platelet and leukocyte levels. This study aims to evaluate the side effect of Paclitaxel-Cisplatin chemotherapy in EOC patients with hematologic status at Sanglah General Hospital, Denpasar. Observational retrospective research was conducted from February-May 2018. Samples were EOC patients who underwent 6 cycles of Paclitaxel-Cisplatin chemotherapy at Sanglah General Hospital, Bali-Indonesia from January 2015-May 2018. Side effects of chemotherapy were seen from hemoglobin, platelet and leukocyte data before and after six cycles of chemotheraphy. Hematologic data were analyzed and compared using Paired T-test with a level of confidence of 95% using the STATA version 14 software. Mean value of three hematologic parameters decreased after six cycles including hemoglobin levels were 12.05 to 10.69 g/dL (p-value=0.282); platelet levels were 378.5 to 326.9 g/dL (p-value=0,569) and leukocyte levels were 11.32 to 8.28 g/dL (p-value=0,517). There were differences of hemoglobin, platelet, leukocyte levels before the first and after the sixth cycle of chemotheraphy. Low side effects of Paclitaxel-Cisplatin was observed in this study (Anemia grade 1).
Key words: Chemotherapy, Paclitaxel-Cisplatin, Epithelial ovarian cancer, Hemoglobin, Platelet, Leukocyte.
|
